| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
866.07(B) |
| Last
Volume: |
3,374,911 |
Avg
Vol: |
3,268,697 |
| 52
Week Range: |
$434.7 - $909.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
1,520,577 |
2,391,327 |
3,771,329 |
6,318,238 |
| Total Sell Value |
$1,284,658,855 |
$1,892,909,435 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
18 |
31 |
50 |
93 |
| End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lechleiter John C |
Director |
– • – |
2016-05-24 |
5 |
GD |
$0.00 |
$0 |
D/D |
1,110 |
735,954 |
|
- |
|
| Lechleiter John C |
Director |
– • – |
2016-05-20 |
5 |
GD |
$0.00 |
$0 |
D/D |
740 |
737,064 |
|
- |
|
| Lechleiter John C |
Director |
– • – |
2016-05-13 |
5 |
GD |
$0.00 |
$0 |
D/D |
3,314 |
737,804 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2016-05-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,080 |
39,520 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2016-05-12 |
4 |
B |
$75.75 |
$81,810 |
D/D |
1,080 |
40,600 |
2.39 |
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2016-05-12 |
4 |
S |
$75.84 |
$14,414,035 |
D/D |
(190,000) |
127,290,804 |
|
- |
|
| Lechleiter John C |
Director |
– • – |
2016-05-11 |
5 |
GD |
$0.00 |
$0 |
D/D |
700 |
741,118 |
|
- |
|
| Lechleiter John C |
Director |
– • – |
2016-05-10 |
5 |
GD |
$0.00 |
$0 |
D/D |
8,690 |
741,818 |
|
- |
|
| Lechleiter John C |
Director |
– • – |
2016-05-09 |
5 |
GD |
$0.00 |
$0 |
D/D |
680 |
750,508 |
|
- |
|
| Zakrowski Donald A |
Chief Accounting Officer |
• – – |
2016-05-02 |
4 |
S |
$76.53 |
$45,918 |
D/D |
(600) |
2,513 |
|
- |
|
| Marram Ellen R |
Director |
– • – |
2016-04-29 |
4 |
A |
$77.22 |
$6,564 |
D/D |
85 |
46,508 |
|
- |
|
| Zakrowski Donald A |
Chief Accounting Officer |
• – – |
2016-04-29 |
4 |
S |
$75.45 |
$75,450 |
D/D |
(1,000) |
3,113 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2016-04-29 |
4 |
A |
$77.22 |
$9,884 |
D/D |
128 |
31,298 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2016-04-29 |
4 |
S |
$75.44 |
$13,580,052 |
D/D |
(180,000) |
127,480,804 |
|
- |
|
| Zulueta Alfonso G |
SVP& Pres., Emerging Markets |
• – – |
2016-04-27 |
4 |
S |
$76.27 |
$915,240 |
D/D |
(12,000) |
45,101 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2016-04-08 |
4 |
S |
$74.29 |
$14,857,800 |
D/D |
(200,000) |
127,660,804 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2016-03-31 |
4 |
A |
$70.25 |
$9,905 |
D/D |
141 |
31,170 |
|
- |
|
| Marram Ellen R |
Director |
– • – |
2016-03-31 |
4 |
A |
$70.25 |
$6,604 |
D/D |
94 |
46,423 |
|
- |
|
| Rice Derica W |
EVP-Global Services and CFO |
• – – |
2016-03-21 |
5 |
GD |
$0.00 |
$0 |
I/I |
78 |
366,059 |
|
- |
|
| Marram Ellen R |
Director |
– • – |
2016-02-29 |
4 |
A |
$73.33 |
$6,526 |
D/D |
89 |
46,003 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2016-02-29 |
4 |
A |
$73.33 |
$9,900 |
D/D |
135 |
30,806 |
|
- |
|
| Rice Derica W |
EVP-Global Services and CFO |
• – – |
2016-02-08 |
5 |
GA |
$0.00 |
$0 |
I/I |
36,931 |
366,137 |
|
- |
|
| Rice Derica W |
EVP-Global Services and CFO |
• – – |
2016-02-08 |
5 |
GD |
$0.00 |
$0 |
D/D |
36,931 |
0 |
|
- |
|
| Fry Stephen F |
SVP, HR & Diversity |
• – – |
2016-02-05 |
4 |
S |
$78.87 |
$1,201,190 |
D/D |
(15,230) |
59,690 |
|
- |
|
| Rice Derica W |
EVP-Global Services and CFO |
• – – |
2016-02-03 |
4 |
AS |
$76.81 |
$302,401 |
D/D |
(3,937) |
36,931 |
|
- |
|
1436 Records found
|
|
Page 46 of 58 |
|
|
3.66 (0.4%) 
